MARATTO

article · International Journal of Surgery Case Reports

Double trouble: Tumor-to-tumor metastasis of breast cancer into a thyroid papillary carcinoma – Case report and review of literature

20251 citationOpen accessUniversity of Tunis El Manar

Abstract

INTRODUCTION AND IMPORTANCE: Tumor-to-tumor metastasis is a rare and challenging phenomenon, particularly involving the thyroid gland. Breast cancer metastasizing into the thyroid gland with a coexisting papillary thyroid carcinoma is an extremely rare situation, with few cases reported in the literature. Our aim was to report a rare incidence of this association, along with a literature review of similar cases. CASE PRESENTATION: We present the case of a 63-year-old woman with a history of invasive lobular breast carcinoma who developed a right thyroid nodule. The patient underwent total thyroidectomy and pathology revealed metastatic breast carcinoma with a coexistent papillary thyroid carcinoma in the same lobe. CLINICAL DISCUSSION: Metastatic breast cancer to the thyroid accounts for only 1 %-3 % of all thyroid malignancies, despite the thyroid's rich vascularity. These metastases can mimic a primary thyroid tumor. Only definitive histology can confirm the metastatic origin in these cases. CONCLUSION: This case highlights the diagnostic and therapeutic challenges encountered when facing tumor-to-tumor metastasis. Despite its rarity, awareness of this entity is crucial and requires close thyroid monitoring in breast cancer survivors.

Research topics

  • Thyroid Cancer Diagnosis and Treatment
  • Breast Lesions and Carcinomas
  • Thyroid and Parathyroid Surgery

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.ijscr.2025.111480

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.